To include your compound in the COVID-19 Resource Center, submit it here.

Lilly reports detailed Phase III data for Cyramza in first-line gastric cancer

Eli Lilly and Co. (NYSE:LLY) reported additional data from the Phase III RAINFALL trial in 645 patients with HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma showing that IV Cyramza ramucirumab (IMC-1121B,

Read the full 311 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers